<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Patient Rep Outcomes</journal-id><journal-id journal-id-type="iso-abbrev">J Patient Rep Outcomes</journal-id><journal-title-group><journal-title>Journal of Patient-Reported Outcomes</journal-title></journal-title-group><issn pub-type="epub">2509-8020</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40402367</article-id><article-id pub-id-type="pmc">PMC12098238</article-id>
<article-id pub-id-type="publisher-id">896</article-id><article-id pub-id-type="doi">10.1186/s41687-025-00896-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Translation, cross-cultural adaptation, and validation of the Norwegian version of the Keratoconus Outcomes Research Questionnaire</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0000-3872-5531</contrib-id><name><surname>Lundanes</surname><given-names>Eilin</given-names></name><address><email>eilin.lundanes@usn.no</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Roten</surname><given-names>Svein Magne</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Falkenberg</surname><given-names>Helle Kristine</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Leren</surname><given-names>Lena</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sundling</surname><given-names>Vibeke</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05ecg5h20</institution-id><institution-id institution-id-type="GRID">grid.463530.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 7417 509X</institution-id><institution>National Centre for Optics, Vision and Eye Care, Department of Optometry, Radiography and Lighting Design, Faculty of Health and Social Sciences, </institution><institution>University of South-Eastern Norway, </institution></institution-wrap>Hasbergsvei 36, Kongsberg, 3616 Norway </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05ecg5h20</institution-id><institution-id institution-id-type="GRID">grid.463530.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 7417 509X</institution-id><institution>Centre for Health and Technology, Department of Nursing and Health Sciences, Faculty of Health and Social Sciences, </institution><institution>University of South-Eastern Norway, </institution></institution-wrap>Gr&#x000f8;nland 58, Drammen, 3045 Norway </aff><aff id="Aff3"><label>3</label>Specsavers Str&#x000f8;mmen, St&#x000f8;periveien 5, Str&#x000f8;mmen, 2010 Norway </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>9</volume><elocation-id>57</elocation-id><history><date date-type="received"><day>23</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>9</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">To translate and adapt the Keratoconus Outcomes Research questionnaire (KORQ) to Norwegian language, culture, and environment, and to validate the translated version in a Norwegian population with keratoconus.</p></sec><sec><title>Methods</title><p id="Par2">KORQ was translated to Norwegian using a multi-step methodology. Persons with keratoconus submitted responses to KORQ-NO and NEI VFQ-25 through a digital platform, and a retest of KORQ-NO was performed over the telephone. Additional data from a clinical intervention study was included. The psychometric properties of KORQ-NO were assessed by Rasch analysis. Test-retest reliability, construct validity, and responsiveness were explored by Intraclass Correlation Coefficients, Spearman correlations and Wilcoxon Signed-rank test.</p></sec><sec><title>Results</title><p id="Par3">KORQ-NO and NEI VFQ-25 were completed by 165 participants with keratoconus. With few adjustments, the &#x0201c;Activity limitations&#x0201d; (AL) and &#x0201c;Symptoms&#x0201d; (S) subscales of KORQ-NO exhibit acceptable psychometric properties with good model fit, high internal reliability, and well-targeted items to the population. Deletion of four items (AL3, AL3b, AL12, AL15) improved dimensionality of the &#x0201c;Activity limitations&#x0201d; subscale. Differential item functioning was present in two items (AL4 and AL6). Participants and optometrists confirmed content validity, and KORQ-NO exhibited good test-retest reliability (AL ICC&#x02009;=&#x02009;0.90 and S ICC&#x02009;=&#x02009;0.81), construct validity, and responsiveness.</p></sec><sec><title>Conclusions</title><p id="Par4">Successful translation and adaptation of KORQ to Norwegian language, culture and environment was confirmed by acceptable psychometric properties, with good validity, reliability, and responsiveness. The authors support the use of KORQ-NO in research, clinical practice, and as documentation for national insurance benefit applications.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s41687-025-00896-z.</p></sec></abstract><abstract id="Abs2" abstract-type="plain-language-summary"><sec><title>Why?</title><p id="Par5">Keratoconus is an eye disease occurring in early adolescence. Persons with keratoconus often have reduced quality-of-life (QoL) despite only subtle changes in visual functions. There is a need of a Norwegian questionnaire to measure vision-related QoL in persons with keratoconus.</p></sec><sec><title>What?</title><p id="Par6">The aim was to translate a vision-related QoL questionnaire specific for keratoconus (KORQ) into Norwegian, and to evaluate the translation.</p></sec><sec><title>Main findings and so what?</title><p id="Par7">This study has shown that the Norwegian translation of the questionnaire works as intended. The questionnaire is relevant for use in research on keratoconus, clinical practice, and for national insurance benefit applications. The Norwegian translation of the questionnaire (KORQ-NO) is freely available.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s41687-025-00896-z.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Keratoconus outcomes research questionnaire</kwd><kwd>Translation</kwd><kwd>Cross-cultural adaptation</kwd><kwd>Validity</kwd><kwd>Reliability</kwd><kwd>Rasch analysis</kwd></kwd-group><funding-group><award-group><funding-source><institution>University Of South-Eastern Norway</institution></funding-source></award-group><open-access><p>Open access funding provided by University Of South-Eastern Norway</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; International Society for Quality of Life Research (ISOQOL) 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par8">Keratoconus is a progressive, chronic corneal disease occurring in early adolescence. Asymmetric corneal thinning and protrusion result in irregular astigmatism, distorted and reduced vision. Common symptoms include polyopia, glare, reduced night vision, photophobia, and eye strain [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The prevalence of keratoconus worldwide ranges from 0.2 to 3300 per 100.000 depending on diagnostic criteria and geographic location [<xref ref-type="bibr" rid="CR3">3</xref>]. In Norway the prevalence is estimated to 192 per 100.000, with an incidence of 20 per 100.000 in the general population [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par9">It is well-established that keratoconus compromises vision-related quality of life (VR-QoL) [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. The visual distortions and symptoms of keratoconus are unpredictable, and clinical measurements, such as visual acuity, are not likely to reflect the impact on visual function [<xref ref-type="bibr" rid="CR5">5</xref>]. Assessment of VR-QoL is challenging as several latent traits may contribute, such as visual symptoms, ocular surface symptoms, general symptoms, emotional well-being, activity limitations, mobility, convenience, health concerns, social and economic well-being and so forth [<xref ref-type="bibr" rid="CR8">8</xref>]. Well-functioning questionnaires, commonly referred to as patient-reported outcome measures (PROMs), may be used to assess such latent traits [<xref ref-type="bibr" rid="CR8">8</xref>]. Many studies have used the National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25), a generic vision-related PROM originally developed for age-related eye disease [<xref ref-type="bibr" rid="CR9">9</xref>], to investigate VR-QoL in keratoconus [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. However, a generic PROM usually has reduced sensitivity with worse validity and responsiveness to change compared to a disease-specific PROM [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par10">Keratoconus Outcomes Research Questionnaire (KORQ) was the first available keratoconus-specific PROM, developed and validated by Khadka and colleges in Australian populations [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. The English version is also validated in a population in India [<xref ref-type="bibr" rid="CR17">17</xref>]. So far, KORQ has been translated to Danish [<xref ref-type="bibr" rid="CR18">18</xref>], Italian [<xref ref-type="bibr" rid="CR19">19</xref>], Portuguese [<xref ref-type="bibr" rid="CR20">20</xref>], Spanish [<xref ref-type="bibr" rid="CR21">21</xref>] and German [<xref ref-type="bibr" rid="CR22">22</xref>]. Most translations exhibit minor issues with multidimensionality of the questionnaire, solved by collapsing or deleting items [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. Studies evaluating KORQ found excellent test-retest reliability [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>] and weak to moderate positive correlations between KORQ and corrected visual acuity [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR22">22</xref>] and steepest corneal curvature [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. To date, no keratoconus-specific PROM is available in Norwegian.</p><p id="Par11">The Norwegian National Insurance Act &#x000a7;&#x000a0;10&#x02009;&#x02212;&#x02009;7 states that persons with keratoconus may receive insurance benefits for specialty contact lenses if visual acuity and/or visual function is significantly improved compared to conventional correction glasses or contact lenses [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Therefore, a validated, keratoconus-specific PROM in Norwegian may not only be useful in research and clinical practice but also serve as a valuable tool for documenting improvements beyond clinical measures for the Norwegian Labour and Welfare Administration when considering insurance benefit applications.</p><p id="Par12">Translation, cross-cultural adaptation, and validation in the target population is important before implementation of a PROM [<xref ref-type="bibr" rid="CR25">25</xref>]. There is no global consensus on cross-cultural adaptation of PROMs [<xref ref-type="bibr" rid="CR26">26</xref>], but a multistep methodology including forward- and back-translation is recommended [<xref ref-type="bibr" rid="CR25">25</xref>]. The Consensus-based Standards for selection of health status Measurement Instruments (COSMIN) checklists can serve as a guide in validation of PROMs [<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>]. The purpose of this study was to translate and adapt KORQ to Norwegian language, culture, and environment, and to validate the translated version in a Norwegian population with keratoconus.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>KORQ, translation and adaptation to Norwegian</title><p id="Par13">KORQ comprises two subscales, the 18 items &#x0201c;Activity limitations&#x0201d; (AL) and the 11 items &#x0201c;Symptoms&#x0201d; (S). All items have a four-point rating scale ranging from 1 to 4; 1&#x02009;=&#x02009;Not at all, 2&#x02009;=&#x02009;A little, 3&#x02009;=&#x02009;Quite a bit, and 4&#x02009;=&#x02009;A lot. A &#x0201c;Not applicable&#x0201d; option, treated as missing data in analysis, is available for all items. Patient demographics are recorded on the front page of the questionnaire. The English version of KORQ is available in Appendix <xref rid="MOESM1" ref-type="media">1</xref>.</p><p id="Par14">The Norwegian translation of KORQ (KORQ-NO) was made with permission from the developers (Khadka). The translation process followed principles described in literature [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>], illustrated in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. The translation was performed concurrent and independently by three Norwegian optometrists fluent in English (SMR, VS and HKF). Two of the translators (VS and HKF) have academic and clinical background from English-speaking countries and are experienced in translation work. Discrepancies in the translations were discussed, and consensus was reached. The Norwegian to English back translation was undertaken by a native English speaking academic fluent in Norwegian. Cognitive debriefing was undertaken with a lay person without background in optometry ensuring comprehensiveness of the content.</p><p id="Par15">
<fig id="Fig1"><label>Fig. 1</label><caption><p>The translation and validation process. <italic>Note:</italic> The translation process is illustrated to the left. Norwegian is the native language of all committee members and translators (SMR, VS and HKF), and all are fluent in English. English is the native language of SG, and SG is fluent in Norwegian. The lay person doing the cognitive debriefing has no background in optometry and vision science. The validation process, in accordance with the COSMIN checklist, is illustrated to the right. For definitions and details of methods used to evaluate each property, please review appendix <xref rid="MOESM2" ref-type="media">2</xref>. Additionally, Rasch analysis was applied, as described in the methods section. * Properties included in the Rasch analysis. <italic>Abbreviations:</italic> KORQ: Keratoconus Outcomes Research Questionnaire, KORQ-NO: The Norwegian version of KORQ, SMR: Svein Magne Roten, Master of Optometry Student, VS: Vibeke Sundling, Professor, HKS: Helle Kristine Falkenberg, Professor, SG: Stuart Gilson, Associate Professor</p></caption><graphic xlink:href="41687_2025_896_Fig1_HTML" id="d33e397"/></fig>
</p></sec><sec id="Sec4"><title>Reliability and validity according to the COSMIN checklist</title><p id="Par16">The Consensus-based standards for the selection of health status measurement instruments (COSMIN) has developed a consensus-based checklist to evaluate the quality of studies on measurement properties [<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>]. The COSMIN checklist was applied to assess reliability and validity of KORQ-NO. Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> gives an overview of the properties assessed, and appendix <xref rid="MOESM2" ref-type="media">2</xref> contains definitions and detailed descriptions of the methods used to evaluate each property. Statistical analysis included Intraclass Correlation Coefficients and Bland-Altman plots with Limits of Agreement, Spearman correlations and Exact Wilcoxon Signed-rank test. IBM Statistical Package for Social Sciences (SPSS, Inc. Chicago, IL, USA for Windows 10 (version 29)) [<xref ref-type="bibr" rid="CR41">41</xref>] was used for statistical analysis.</p></sec><sec id="Sec5"><title>Rasch measurement theory</title><p id="Par17">KORQ-NO was assessed using Rasch Measurement Theory in accordance with the development study of the original KORQ [<xref ref-type="bibr" rid="CR15">15</xref>] and several other validation studies [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Rasch measurement theory is a probabilistic, mathematical model commonly used to assess the psychometric properties of PROMs [<xref ref-type="bibr" rid="CR34">34</xref>]. The model has three requirements for valid estimates; unidimensionality, invariance, and ordered response categories [<xref ref-type="bibr" rid="CR35">35</xref>]. Ordinal scores are transformed to a linear logit scale, essential for creating sum scores and calculating change scores or standard deviations. Estimates of the relative difficulty of each item (item location) and the relative ability of each respondent (person location) are placed on a common logit scale [<xref ref-type="bibr" rid="CR36">36</xref>]. With the scoring of KORQ-NO, lower person location logits relate to less impact on VR-QoL, whereas lower item location logits suggest more difficult items.</p><p id="Par18">Rasch analysis were performed using RUMM 2030&#x02009;+&#x02009;for Windows (RUMM Laboratory, Australia, version 5.8.1) [<xref ref-type="bibr" rid="CR37">37</xref>]. The &#x0201c;Activity limitations&#x0201d; and &#x0201c;Symptoms&#x0201d; subscales of KORQ-NO were analysed independently by the polytomous partial credit model of Rasch [<xref ref-type="bibr" rid="CR38">38</xref>]. NEI VFQ-25 was analysed by the same model. An overview of the properties included in the Rasch analysis with expected values is provided in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. A large sample size is required for robust Rasch; however, the impact of sample size varies across different properties. Recommendations are included in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par19">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Overview of the Rasch analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Rasch analysis</th><th align="left">Function name</th><th align="left">Expected values<break/>&#x00026; sample size<break/>recommendations</th></tr></thead><tbody><tr><td align="left">Overall model fit</td><td align="left">Item-trait interaction</td><td align="left">X<sup>2</sup><italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05/# items confirms that the data is not statistically different from the model [<xref ref-type="bibr" rid="CR38">38</xref>]</td></tr><tr><td align="left"><p>Reliability</p><p>
<italic>Comparable to Cronbach&#x02019;s &#x003b1;</italic>
</p></td><td align="left">Person Separation Index (PSI)</td><td align="left"><p>&#x0003e;&#x02009;0.85 is indicative of the ability of the scale to separate persons along the trait [<xref ref-type="bibr" rid="CR34">34</xref>]</p><p>Vaguely impacted by sample size [<xref ref-type="bibr" rid="CR39">39</xref>]</p></td></tr><tr><td align="left"><p>
<bold><italic>Unidimensionality</italic></bold>
</p><p>
<italic>Measurement of one latent trait only</italic>
</p></td><td align="left">Principal Component Analysis (PCA)</td><td align="left"><p>Proportion of statistically significant <italic>t</italic>-tests&#x02009;&#x0003c;&#x02009;5% [<xref ref-type="bibr" rid="CR34">34</xref>]</p><p>Eigenvalue of the first principal component&#x02009;&#x0003c;&#x02009;2.0&#x02013;3.0 [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]</p></td></tr><tr><td align="left">Response dependency</td><td align="left">Correlations of item residuals</td><td align="left">Correlations 0.2 above the mean item residuals indicate dependency, hence item redundancy [<xref ref-type="bibr" rid="CR40">40</xref>]</td></tr><tr><td align="left" rowspan="5"><p>
<bold><italic>Invariance</italic></bold>
</p><p>
<italic>Equal performance of items across various person factors or groups</italic>
</p></td><td align="left">Differential Item Functioning (DIF)</td><td align="left">Statistically significant differences among mean residuals indicate DIFs (Bonferroni-adjusted p-value&#x02009;&#x0003c;&#x02009;0.05) [<xref ref-type="bibr" rid="CR40">40</xref>]. The following person factors included:</td></tr><tr><td align="left" rowspan="4"/><td align="left">&#x02003;- Age (under/on vs. above mean age)</td></tr><tr><td align="left">&#x02003;- Sex (female vs. male)</td></tr><tr><td align="left">&#x02003;- Visual correction type (uncorrected/spectacles/soft contact lenses vs. rigid gas permeable lenses)</td></tr><tr><td align="left"><p>&#x02003;- History of treatment (yes vs. no)</p><p>Recommended sample size: 100 to 300 per subgroup [<xref ref-type="bibr" rid="CR35">35</xref>]</p></td></tr><tr><td align="left">
<bold><italic>Ordered response categories</italic></bold>
</td><td align="left"><p>Item threshold parameters</p><p>Category probability curves</p></td><td align="left"><p>Well-separated and ordered thresholds [<xref ref-type="bibr" rid="CR38">38</xref>]</p><p>Recommended sample size: At least 10 responses per response category [<xref ref-type="bibr" rid="CR35">35</xref>]</p></td></tr><tr><td align="left">Targeting</td><td align="left"><p>Mean persons location</p><p>Person-item threshold distribution graphs</p></td><td align="left"><p>Close to 0, when mean items location set to 0 by default, indicates good targeting to the population [<xref ref-type="bibr" rid="CR40">40</xref>]</p><p>Close alignment between persons and items along the logit scale indicates good targeting [<xref ref-type="bibr" rid="CR40">40</xref>]</p></td></tr><tr><td align="left">Item fit</td><td align="left">Item fit residuals</td><td align="left"><p>Items with fit residuals within +/-2.50 with low X<sup>2</sup> and Bonferroni adjusted <italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05 fit the model [<xref ref-type="bibr" rid="CR40">40</xref>]</p><p>Recommended sample size: &#x0003e;200 [<xref ref-type="bibr" rid="CR35">35</xref>]</p></td></tr><tr><td align="left">Person fit</td><td align="left">Person fit residuals</td><td align="left">Person misfit is indicated when fit residuals +/- &#x0221e;, marked as extreme [<xref ref-type="bibr" rid="CR40">40</xref>]</td></tr></tbody></table><table-wrap-foot><p>Note: Requirements of the Rasch model include unidimensionality, invariance and ordered response categories</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec6"><title>Recruitment, data collection and ethics</title><p id="Par20">Persons with keratoconus aged 18 years and older were invited to participate through a social media user group, &#x0201c;Keratoconus Norway&#x0201d;. &#x0201c;Nettskjema&#x0201d;, a digital platform provided by the University of Oslo, was utilized to distribute two self-reporting questionnaires on VR-QoL: the disease-specific KORQ-NO, and the vision-generic NEI VFQ-25 [<xref ref-type="bibr" rid="CR32">32</xref>]. NEI VFQ-25 was included to enable assessment of construct validity of KORQ-NO. Participants were asked to leave their telephone number for a retest of KORQ-NO. Three to four weeks after initial completion of the questionnaires, the first author (EL) contacted the participants to repeat KORQ-NO and collect quantitative data to facilitate assessment of test-retest reliability and content validity. In addition, data from a clinical intervention study (Manuscript submitted for publication) were included to allow assessment of construct validity and responsiveness.</p><p id="Par21">All participants provided written informed consent. The research was conducted in accordance with the Helsinki declaration [<xref ref-type="bibr" rid="CR33">33</xref>]. Both the current study and the clinical intervention study were approved by the Norwegian Center for research data (SiKT reference number 934897 &#x00026; 953377), and the intervention study was approved by the Regional Committee for Medical Research Ethics (REK 953377).</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Translation, cross-cultural and environmental adaptation</title><p id="Par22">The three, concurrent, independent Norwegian translations possessed few differences, and the consensus process was straightforward. There were very few minor differences between the original version of KORQ and the English back-translation from the Norwegian translation. The translators discussed the term &#x0201c;computer screen&#x0201d; in AL1 and agreed to adjust the term to &#x0201c;digital devises&#x0201d; to account for constant changes in technology. Due to weather differences between Australia and Norway, the translators decided to add a question AL3b: <italic>&#x0201c;How much does your vision interfere with driving in poor visibility (rain/snow/fog)?&#x0201d;</italic>. Items such as S2 <italic>&#x0201c;How much are you troubled by glare?&#x0201d;</italic> and S3 <italic>&#x0201c;How much does a bright sunny day interfere with your ability to see?&#x0201d;</italic> were thoroughly discussed, but the items were kept because light reflections on snow during winter can be intense. The phrase <italic>&#x0201c;windy days&#x0201d;</italic> in item S7 was adjusted to <italic>&#x0201c;a lot of wind&#x0201d;</italic>, and the phrases <italic>&#x0201d;dry/dusty days&#x0201d;</italic> in items S9 and S10 were changed to <italic>&#x0201c;dry air&#x0201d;</italic> and <italic>&#x0201d;a lot of dust in the air&#x0201d;</italic> for better accuracy in Norwegian. The adjustments were included in the final version of KORQ-NO prior to data collection for validation.</p></sec><sec id="Sec9"><title>Demography</title><p id="Par23">In total, 165 participants completed KORQ-NO and NEI VFQ-25,136 through &#x0201c;Nettskjema&#x0201d; and 29 as part of the clinical intervention study. Seventeen participants completed the retest of KORQ-NO. Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> presents an overview of demographics. There were no statistically significant differences in sex or age between the groups. The retest group had significantly more participants using contact lenses and fewer participants with history of surgical treatment.</p><p id="Par24">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Demographic characteristics of the participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">
<bold>Demography</bold>
</th><th align="left">All participants</th><th align="left">Retest group</th><th align="left">Clinical group</th><th align="left" colspan="2">Chi-square statistics</th></tr><tr><th align="left"><italic>n</italic>&#x02009;=&#x02009;165</th><th align="left"><italic>n</italic>&#x02009;=&#x02009;17</th><th align="left"><italic>n</italic>&#x02009;=&#x02009;29</th><th align="left">All vs. Retest</th><th align="left">All vs. Clinical</th></tr></thead><tbody><tr><td align="left" colspan="6"><bold>Sex</bold>,<bold> n (%)</bold></td></tr><tr><td align="left">Female</td><td align="left">80 (48.5)</td><td align="left">5 (29.4)</td><td align="left">7 (24.1)</td><td align="left">X<sup>2</sup>=0.29</td><td align="left">X<sup>2</sup>=4.16</td></tr><tr><td align="left">Male</td><td align="left">85 (51.5)</td><td align="left">12 (70.6)</td><td align="left">22 (76.9)</td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.86</td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.13</td></tr><tr><td align="left" colspan="6">
<bold>Age</bold>
</td></tr><tr><td align="left">Median</td><td align="left">41</td><td align="left">42</td><td align="left">34</td><td align="left">X<sup>2</sup>=153.00</td><td align="left">X<sup>2</sup>=372.97</td></tr><tr><td align="left">Range</td><td align="left">19&#x02013;72</td><td align="left">29&#x02013;61</td><td align="left">20&#x02013;68</td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.27</td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.32</td></tr><tr><td align="left" colspan="6"><bold>Optical correction</bold>,<bold> n (%)</bold><sup><bold>a</bold></sup></td></tr><tr><td align="left">No correction</td><td align="left">9 (5.5)</td><td align="left">1 (5.9)</td><td align="left">5 (17.2)</td><td align="left">X<sup>2</sup>=13.03</td><td align="left">X<sup>2</sup>=6.07</td></tr><tr><td align="left">Spectacles</td><td align="left">43 (26.1)</td><td align="left">2 (11.7)</td><td align="left">14 (48.3)</td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.04*</td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.73</td></tr><tr><td align="left">Soft Contact Lenses</td><td align="left">18 (10.9)</td><td align="left">3 (17.6)</td><td align="left">2 (6.9)</td><td align="left"/><td align="left"/></tr><tr><td align="left">Rigid Contact Lenses</td><td align="left">95 (57.6)</td><td align="left">11 (64.7)</td><td align="left">8 (27.6)</td><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="6"><bold>Surgical treatment</bold>,<bold> n (%)</bold><sup><bold>b</bold></sup></td></tr><tr><td align="left">No treatment</td><td align="left">77 (46.7)</td><td align="left">9 (52.9)</td><td align="left">18 (62.1)</td><td align="left">X<sup>2</sup>=0.94</td><td align="left">X<sup>2</sup>=13.79</td></tr><tr><td align="left">Corneal crosslinking (CXL)</td><td align="left">57 (34.5)</td><td align="left">6 (35.3)</td><td align="left">10 (34.5)</td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.92</td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.008**</td></tr><tr><td align="left">Corneal transplant (CT)</td><td align="left">27 (16.4)</td><td align="left">2 (11.8)</td><td align="left">0 (0.0)</td><td align="left"/><td align="left"/></tr><tr><td align="left">Intracorneal ring segments</td><td align="left">2 (1.2)</td><td align="left">0 (0.0)</td><td align="left">1 (3.4)</td><td align="left"/><td align="left"/></tr><tr><td align="left">Missing data</td><td align="left">2 (1.2)</td><td align="left">0 (0.0)</td><td align="left">0 (0.0)</td><td align="left"/><td align="left"/></tr></tbody></table><table-wrap-foot><p>Notes: Significance levels: *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01</p><p><sup>a</sup> Participants reporting the use of more than one optical correction type were counted as follows: Participants using rigid contact lenses and/or soft contact lenses and/or spectacles were placed in the rigid contact lenses group. Participants using soft contact lenses and spectacles were placed in the soft contact lenses group. Participants using spectacles only were placed in the spectacles group</p><p><sup>b</sup> Participants reporting more than one surgical treatment were counted as follows: Participants with history of corneal crosslinking and corneal transplantation were placed in the corneal transplantation group. Participants with history of corneal crosslinking only were placed in the corneal crosslinking group</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec10"><title>The Rasch analysis</title><p id="Par25">Results from the Rasch analysis of &#x0201c;Activity limitations&#x0201d; and &#x0201c;Symptoms&#x0201d; subscales, and NEI VFQ-25, are summarized in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. The Rasch analysis revealed several issues with the psychometric properties of the &#x0201c;Activity limitations&#x0201d; subscale as the overall fit to the model was poor, multidimensionality was indicated, and response dependency was evident between one item pair, AL3 <italic>&#x0201c;driving at night&#x0201d;</italic> and AL3b <italic>&#x0201c;driving in poor visibility&#x0201d;</italic> (<italic>r</italic>&#x02009;=&#x02009;0.537). Most items did not differ across the person factors. However, AL 4 <italic>&#x0201c;reading signs&#x0201d;</italic> displayed statistically significant Differential Item Functioning (DIF) by age (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) with higher scores in the older age group and AL 6 <italic>&#x0201c;walking in stairs&#x0201d;</italic> displayed statistically significant DIF by sex (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) with higher scores in females.</p><p id="Par26">On the contrary, the psychometric properties of the &#x0201c;Symptoms&#x0201d; subscale were good. The proportions of statistically significant <italic>t-</italic>tests were slightly above the limit, but the eigenvalue of the first contrast was acceptable for unidimensionality. Both subscales exhibit excellent reliability with high Person Separation Index (PSI).</p><p id="Par27">NEI VFQ-25 did not fulfil any of the requirements of Rasch, with presence of multidimensionality, invariance for item 9 <italic>&#x0201c;Walking down steps</italic>,<italic> stairs or curbs in reduced lighting or darkness&#x0201d;</italic>, and disordered thresholds for 12 of the items.</p><p id="Par28">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Summary of Rasch analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"/><th align="left" colspan="2">Overall fit</th><th align="left">Reliability</th><th align="left" colspan="2">Unidimensionality</th><th align="left">Response dependency</th><th align="left">Invariance</th><th align="left">Response categories</th><th align="left">Targeting</th><th align="left">Item misfit</th><th align="left">Person misfit</th></tr><tr><th align="left" colspan="2">Item-trait interaction</th><th align="left">PSI</th><th align="left" colspan="2">Principal Component Analysis</th><th align="left"/><th align="left">DIF</th><th align="left" rowspan="2"># items disordered</th><th align="left" rowspan="2">Mean persons location [SD]</th><th align="left"/><th align="left"/></tr><tr><th align="left">Chi-square</th><th align="left">
<italic>p</italic>
</th><th align="left"/><th align="left">% stat. sign. t-tests</th><th align="left">Eigenvalue of 1st contrast</th><th align="left"># item pairs</th><th align="left"/><th align="left"># items</th><th align="left"># persons</th></tr></thead><tbody><tr><td align="left">Activity Limitations</td><td char="." align="char">64.39</td><td char="." align="char">0.005</td><td char="." align="char">0.94</td><td char="." align="char">12.73</td><td char="." align="char">2.57</td><td char="." align="char">1</td><td align="left"><p>By age: AL4<sup>a</sup></p><p>By sex: AL6<sup>a</sup></p></td><td align="left">1 <sup>c</sup></td><td char="." align="char">-0.07 [1.66]</td><td align="left">1<sup>d</sup></td><td char="." align="char">3</td></tr><tr><td align="left">Symptoms</td><td char="." align="char">33.92</td><td char="." align="char">0.05</td><td char="." align="char">0.85</td><td char="." align="char">6.67</td><td char="." align="char">2.08</td><td char="." align="char">0</td><td align="left"/><td align="left">0</td><td char="." align="char">0.35 [1.17]</td><td align="left">0</td><td char="." align="char">1</td></tr><tr><td align="left">NEI VFQ-25</td><td char="." align="char">120.00</td><td char="." align="char">&#x0003c;&#x02009;0.001</td><td char="." align="char">0.94</td><td char="." align="char">18.79</td><td char="." align="char">3.46</td><td char="." align="char">6</td><td align="left">By sex: N9<sup>b</sup></td><td align="left">12</td><td char="." align="char">-2.28 [1.23]</td><td align="left">3<sup>e</sup></td><td char="." align="char">0</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: PSI: Person Separation Index, DIF: Differential Item Functioning, SD: standard deviation</p><p><sup>a</sup> AL4 &#x0201c;Reading signs&#x0201d;, AL6 &#x0201c;Walking in stairs&#x0201d;; <sup>b</sup> N9 &#x0201c;Walking down steps, stairs, or curbs in reduced lighting or darkness&#x0201d;; <sup>c</sup> Item with disordered thresholds: AL 15 &#x0201c;Doing household tasks&#x0201d;; <sup>d</sup> Misfitting item: AL12 &#x0201c;Doing your hobbies&#x0201d;; <sup>e</sup> Misfitting items: N1 &#x0201c;Overall health&#x0201d;, N4 &#x0201c;Pain or discomfort in or around the eyes&#x0201d;, N24 &#x0201c;Dependent on help from others&#x0201d;</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec11"><title>Response categories</title><p id="Par29">All items demonstrated well-functioning response categories with ordered and well-spaced thresholds, except AL15 <italic>&#x0201c;doing household tasks&#x0201d;</italic>. Most participants (56.4%) responded &#x0201c;not at all&#x0201d; to this item, and only two participants (1.2%) responded &#x0201c;a lot.&#x0201d; Response frequency tables are available (Appendix <xref rid="MOESM3" ref-type="media">3</xref>).</p></sec><sec id="Sec12"><title>Targeting, item fit, and person fit</title><p id="Par30">The mean person locations confirm good targeting to the study population for both subscales and poor targeting for NEI VFQ-25. Only one item, AL12 <italic>&#x0201c;doing your hobbies&#x0201d;</italic>, displayed individual item misfit (fit residual&#x02009;=&#x02009;3.667, <italic>p</italic>&#x02009;=&#x02009;0.04). Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> illustrates how the KORQ-NO items and persons fit well along the logit scale with very few outliers, whereas several items of NEI VFQ-25 do not fit the population.</p><p id="Par31">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Targeting. <italic>Note:</italic> Person-item distribution for (<bold>a</bold>) &#x0201c;Activity limitations&#x0201d; (top), (<bold>b</bold>) &#x0201c;Symptoms&#x0201d; (middle), and (<bold>c</bold>) NEI VFQ-25 (bottom), illustrating superior targeting of &#x0201c;Activity limitations&#x0201d; and &#x0201c;Symptoms&#x0201d; over NEI VFQ-25. Negative logit person locations indicate less activity limitations and symptoms (better VR-QoL), whereas positive logit person locations indicate more limitations or symptoms (lower VR-QoL). Items with negative logit location indicate more demanding activities or severe symptoms, and positive logit locations indicate easier activities or less severe symptoms</p></caption><graphic xlink:href="41687_2025_896_Fig2_HTML" id="d33e1305"/></fig>
</p></sec><sec id="Sec13"><title>Iterative Rasch analysis for improvement of psychometric properties</title><p id="Par32">To improve overall fit and dimensionality of the &#x0201c;Activity limitations&#x0201d; subscale, items were deleted one by one followed by iterative Rasch analysis. First, item AL3b <italic>&#x0201c;driving in poor visibility&#x0201d;</italic> was removed due to the response dependency. Thereafter, AL3 <italic>&#x0201c;driving at night&#x0201d; was removed as r</italic>esponse dependency appeared between AL2 <italic>&#x0201c;driving in daylight&#x0201d;</italic> and AL3. Due to item misfit and disordered response thresholds respectively, items AL12 <italic>&#x0201c;doing your hobbies&#x0201d;</italic> and AL15 <italic>&#x0201c;doing household tasks&#x0201d;</italic> were removed. Deletion resulted in better overall fit as well as improvements in unidimensionality and response dependency. Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> presents a summary of statistics after removal of items.</p><p id="Par33">
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Summary of results from iterative Rasch analysis of &#x0201c;activity limitations&#x0201d;</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"/><th align="left" colspan="2">Overall fit</th><th align="left">Reliability</th><th align="left" colspan="2">Unidimensionality</th><th align="left">Response dependency</th><th align="left">Invariance</th><th align="left">Response categories</th><th align="left">Targeting</th><th align="left">Item misfit</th><th align="left">Person misfit</th></tr><tr><th align="left" colspan="2">Item-trait interaction</th><th align="left">PSI</th><th align="left" colspan="2">Principal Component Analysis</th><th align="left"/><th align="left">DIF</th><th align="left" rowspan="2"># items disordered</th><th align="left" rowspan="2">Mean persons location [SD]</th><th align="left"/><th align="left"/></tr><tr><th align="left">Chi-square</th><th align="left">
<italic>P</italic>
<sup>a</sup>
</th><th align="left"/><th align="left">% stat. sign. t-tests</th><th align="left">Eigenvalue of 1st contrast</th><th align="left"># item pairs</th><th align="left"/><th align="left"># items</th><th align="left"># persons</th></tr></thead><tbody><tr><td align="left">Initial AL subscale</td><td char="." align="char">64.39</td><td align="left">0.00003</td><td char="." align="char">0.94</td><td align="left">12.72</td><td align="left">2.57</td><td char="." align="char">1</td><td align="left"><p>By age: AL4</p><p>By sex: AL6</p></td><td char="." align="char">1</td><td align="left">-0.07 [1.66]</td><td char="." align="char">1</td><td char="." align="char">3</td></tr><tr><td align="left">Remove AL3b</td><td char="." align="char">49.78</td><td align="left">0.003*</td><td char="." align="char">0.94</td><td align="left">13.33</td><td align="left">2.41</td><td char="." align="char">1</td><td align="left">No change</td><td char="." align="char">1</td><td align="left">-0.13 [1.63]</td><td char="." align="char">1</td><td char="." align="char">3</td></tr><tr><td align="left">Remove AL 3</td><td char="." align="char">40.59</td><td align="left">0.012*</td><td char="." align="char">0.93</td><td align="left">13.94</td><td align="left">2.37</td><td char="." align="char">0</td><td align="left">No change</td><td char="." align="char">1</td><td align="left">-0.20 [1.60]</td><td char="." align="char">1</td><td char="." align="char">3</td></tr><tr><td align="left">Remove AL12</td><td char="." align="char">39.05</td><td align="left">0.011*</td><td char="." align="char">0.93</td><td align="left">7.27</td><td align="left">2.38</td><td char="." align="char">0</td><td align="left">No change</td><td char="." align="char">1</td><td align="left">-0.18 [1.67]</td><td char="." align="char">0</td><td char="." align="char">4</td></tr><tr><td align="left">Remove AL15</td><td char="." align="char">33.17</td><td align="left">0.021*</td><td char="." align="char">0.93</td><td align="left">2.42</td><td align="left">2.27</td><td char="." align="char">0</td><td align="left">No change</td><td char="." align="char">0</td><td align="left">-0.06 [1.68]</td><td char="." align="char">0</td><td char="." align="char">4</td></tr><tr><td align="left">Ideal values</td><td align="left"/><td align="left">&#x0003e;&#x02009;0.05/ #items</td><td char="." align="char">&#x0003e;&#x02009;0.85</td><td align="left">&#x0003c;&#x02009;5%</td><td align="left">&#x0003c;&#x02009;2.00 to &#x0003c;&#x02009;3.00</td><td char="." align="char">0</td><td align="left"/><td char="." align="char">0</td><td align="left">Close to 0</td><td char="." align="char">0</td><td char="." align="char">0</td></tr></tbody></table><table-wrap-foot><p>Note: *not statistically significant, indicate acceptable overall fit to the Rasch model</p><p><sup>a</sup>Bonferroni corrected p-values. Ideal values: 19 items&#x02009;=&#x02009;&#x0003e;&#x02009;0.0026, 18 items&#x02009;=&#x02009;&#x0003e;&#x02009;0.0028, 17 items&#x02009;=&#x02009;&#x0003e;&#x02009;0.0029, 16 items&#x02009;=&#x02009;&#x0003e;&#x02009;0.0031, 15 items&#x02009;=&#x02009;&#x0003e;&#x02009;0.0033</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec14"><title>The COSMIN checklist</title><sec id="Sec15"><title>Reliability; internal consistency, test-retest reliability, and measurement error</title><p id="Par34">The above-mentioned results from the Rasch analysis support acceptable levels of internal consistency of KORQ-NO. &#x0201c;Activity limitations&#x0201d; ICC&#x02009;=&#x02009;0.90 (95% confidence intervals 0.73&#x02013;0.96) indicates good to excellent test-retest reliability. &#x0201c;Symptoms&#x0201d; ICC&#x02009;=&#x02009;0.81 (95% confidence intervals 0.47&#x02013;0.93) indicates low test-retest reliability due to the large confidence intervals. The Bland-Altman plots (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>) illustrate acceptable limits of agreement between the test and retest person locations for both &#x0201c;Activity limitations&#x0201d; (linear regression coefficient&#x02009;=&#x02009;0.08, t&#x02009;=&#x02009;0.046, <italic>p</italic>&#x02009;=&#x02009;0.964) and &#x0201c;Symptoms&#x0201d; (linear regression coefficient&#x02009;=&#x02009;0.154, t&#x02009;=&#x02009;0.679, <italic>p</italic>&#x02009;=&#x02009;0.508).</p><p id="Par35">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Test-retest reliability illustrated by Bland-Altman plots. <italic>Note:</italic> Bland-Altman plots for &#x0201c;Activity limitations&#x0201d; (right) and &#x0201c;Symptoms&#x0201d; (left) show the mean differences between the test and retest results (light green) and the upper and lower limits of agreement (dark green). Each participant is represented by a purple dot. As most participants are within the upper and lower limits of agreement, with no linear correlation, acceptable test-retest reliability is confirmed</p></caption><graphic xlink:href="41687_2025_896_Fig3_HTML" id="d33e1601"/></fig>
</p></sec></sec><sec id="Sec16"><title>Content and construct validity</title><p id="Par36">The seventeen retest participants confirmed relevance of most items of KORQ-NO. One participant articulated that <italic>&#x0201c;this questionnaire describes my life perfectly&#x0201d;</italic>. Both female and male participants perceived the item AL15 <italic>&#x0201c;doing household tasks (e.g. cleaning</italic>,<italic> ironing</italic>,<italic> washing</italic>,<italic> washing up)&#x0201d;</italic> as irrelevant, claiming their vision did not affect the ability to perform such tasks. In the back-translation from Norwegian to English the same item was phrased <italic>&#x0201c;to do housework (e.g. cleaning</italic>,<italic> ironing</italic>,<italic> washing&#x0201d;)</italic>, closely resembling the original item. Itching, dizziness, nausea, and exhaustion were symptoms participants mentioned as important to them but lacking in KORQ-NO. Face validity was questioned as the questionnaire does not include instructions. Participants using more than one type of optical correction would answer the questions differently depending on correction type. Fluctuations in symptoms are not covered by KORQ-NO, and several participants expressed uncertainty whether to respond based on their best day, worst day, or something in between.</p><p id="Par37">The experienced optometrists&#x02019; comments pointed to irrelevance of item AL6 <italic>&#x0201c;walking up/down steps&#x0201d;</italic> and AL7 <italic>&#x0201c;walking onto things&#x0201d;</italic> as these issues are rarely reported in the clinic. One of the optometrists thought AL18 <italic>&#x0201c;use of a camera</italic>,<italic> microscope</italic>,<italic> binoculars etc.&#x0201d;</italic> was confusing, as it could be related to low-vision aids, not commonly used by persons with keratoconus. Except item S4 &#x0201c;<italic>How much are you troubled by wearing rigid gas permeable contact lenses?</italic>&#x0201d;, KORQ-NO does not include contact lens specific items. This was seen as a strength by two optometrists, whereas the third optometrist argued that the questionnaire should cover more contact lens specific aspects.</p><p id="Par38">Construct validity, including structural and cross-cultural validity was confirmed by the abovementioned results of the Rasch analysis. Spearman correlations between the RUMM2030&#x02009;+&#x02009;calculated person locations and the person locations given by the ready-made spreadsheets by the KORQ developers [<xref ref-type="bibr" rid="CR15">15</xref>] were close to perfect for both &#x0201c;Activity limitations&#x0201d; (r<sub>s</sub>= 0.998, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and &#x0201c;Symptoms&#x0201d; (r<sub>s</sub>= 0.994, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), suggesting excellent cross-cultural validity. Also, Spearman correlations suggest strong negative correlations between &#x0201c;Activity limitations&#x0201d; person locations and NEI VFQ-25 sum scores (r<sub>s</sub>= -0.844, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and &#x0201c;Symptoms&#x0201d; person locations and NEI VFQ-25 sum scores (r<sub>s</sub>= -0.714, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001).</p><p id="Par39">Calculations of Spearman correlations between person locations for both subscales and four clinical measurements at baseline, indicate no statistically significant correlations, except a weak correlation between &#x0201c;Activity limitations&#x0201d; and near visual acuity (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>).</p><p id="Par40">
<table-wrap id="Tab5"><label>Table 5</label><caption><p>Spearman correlations between KORQ-NO and clinical measurements</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Spearman correlations</th><th align="left">Binocular DVA<break/><italic>r</italic><sub>s</sub> (<italic>p</italic>)</th><th align="left">Binocular NVA<break/><italic>r</italic><sub>s</sub> (<italic>p</italic>)</th><th align="left">Asymmetry<break/><italic>r</italic><sub>s</sub> (<italic>p</italic>)</th><th align="left">Binocular CS<break/><italic>r</italic><sub>s</sub> (<italic>p</italic>)</th></tr></thead><tbody><tr><td align="left">Activity limitations</td><td char="." align="char">0.091(0.635)</td><td char="." align="char">0.368 (0.05)*</td><td char="." align="char">0.088 (0.649)</td><td char="." align="char">-0.235 (0.221)</td></tr><tr><td align="left">Symptoms</td><td char="." align="char">-0.153 (0.429)</td><td char="." align="char">0.193 (0.316)</td><td char="." align="char">-0.161(0.405)</td><td char="." align="char">0.050 (0.796)</td></tr></tbody></table><table-wrap-foot><p>Note: Spearman correlations show no statistically significant correlations between person locations on &#x0201c;Activity limitations&#x0201d; and &#x0201c;Symptoms&#x0201d; subscales and clinical measurements, except between &#x0201c;Activity limitations&#x0201d; and near visual acuity</p></table-wrap-foot></table-wrap>
</p><p id="Par41">Most participants in the clinical study had no visual impairment and normal contrast sensitivity, indicative of mild stages of keratoconus. Figure&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref> illustrates the distribution of participants in four groups for distance and near visual acuity, contrast sensitivity and asymmetry.</p><p id="Par42">
<fig id="Fig4"><label>Fig. 4</label><caption><p>Distribution of participants on clinical measurements. <italic>Note:</italic> Group numbers relate to the following classifications: Distance and near visual acuity (logMAR): Group 1&#x02009;=&#x02009;No vision impairment (VA&#x02009;&#x0003c;&#x02009;0.00-0.28), Group 2&#x02009;=&#x02009;Mild vision impairment (VA 0.30&#x02013;0.48), Group 3&#x02009;=&#x02009;Moderate vision impairment (VA 0.50&#x02013;1.28) and Group 4&#x02009;=&#x02009;Blindness (VA&#x02009;&#x0003e;&#x02009;1.30). Contrast sensitivity: Group 1&#x02009;=&#x02009;Normal (CS 1.92&#x02013;1.72), Group 2&#x02009;=&#x02009;Normal Age 60+ (CS 1.67&#x02013;1.52), Group 3&#x02009;=&#x02009;Moderate reduction (CS 1.48&#x02013;1.04), Group 4&#x02009;=&#x02009;Severe reduction (CS 0.52-1.00). Asymmetry: Group 1&#x02009;=&#x02009;&#x0003c;&#x02009;1 line, Group 2&#x02009;=&#x02009;1&#x02013;2 lines, Group 3&#x02009;=&#x02009;2&#x02013;3 lines, Group 4&#x02009;=&#x02009;&#x0003e;&#x02009;3 lines</p></caption><graphic xlink:href="41687_2025_896_Fig4_HTML" id="d33e1784"/></fig>
</p><p id="Par43">There were no statistically significant differences in person locations between any of the groups for all clinical measurements (all X<sup>2</sup> p-values&#x02009;&#x0003e;&#x02009;0.05), except between &#x0201c;Activity Limitations&#x0201d; and asymmetry (X<sup>2</sup> = 87.00, <italic>p</italic>&#x02009;=&#x02009;0.01). The distributions of person locations (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>) indicate that persons with reduced contrast sensitivity (group 2 and 3) and persons with low to moderate asymmetry between the eyes (group 2 and 3) have higher person locations, hence lower VR-QoL, on the &#x0201c;Activity limitations&#x0201d; subscale, compared to the participants with normal contrast sensitivity and no asymmetry between the eyes. The same patterns are evident for the &#x0201c;Symptoms&#x0201d; subscale, however, the participants in group 2 and 3 have person locations closer to the mean of group 1, indicating less correlation between visual function and subjective symptoms.</p><p id="Par44">
<fig id="Fig5"><label>Fig. 5</label><caption><p>Distribution of person locations by groups for contrast sensitivity and asymmetry in visual acuity. <italic>Note:</italic> The y-axis presents the person locations. Each dot represents one participant. The lines indicate the mean of each group. The graphs suggest that persons with normal contrast sensitivity have lower person locations (better VR-QoL) on both &#x0201c;Activity limitations&#x0201d; and &#x0201c;Symptoms&#x0201d; subscales, whereas persons with mild asymmetry in visual acuity (group 2 and 3) have higher person locations (lower VR-QoL) on both subscales. Contrast sensitivity: Group 1&#x02009;=&#x02009;Normal (CS 1.92&#x02013;1.72), Group 2&#x02009;=&#x02009;Normal Age 60+ (CS 1.67&#x02013;1.52), Group 3&#x02009;=&#x02009;Moderate reduction (CS 1.48&#x02013;1.04), Group 4&#x02009;=&#x02009;Severe reduction (CS 0.52-1.00). Asymmetry: Group 1&#x02009;=&#x02009;&#x0003c;&#x02009;1 line, Group 2&#x02009;=&#x02009;1&#x02013;2 lines, Group 3&#x02009;=&#x02009;2&#x02013;3 lines, Group 4&#x02009;=&#x02009;&#x0003e;&#x02009;3 lines</p></caption><graphic xlink:href="41687_2025_896_Fig5_HTML" id="d33e1810"/></fig>
</p></sec><sec id="Sec17"><title>Responsiveness</title><p id="Par45">The Exact Wilcoxon Signed-rank test between person locations at baseline and six months after intervention show statistically significant z-values for both subscales, z = -3.903 (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and z = -4.703 (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), respectively, indicating that KORQ-NO can detect change over time (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). NEI VFQ-25 had comparable responsiveness (z = -4.42, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001).</p><p id="Par46">
<fig id="Fig6"><label>Fig. 6</label><caption><p>Responsiveness of KORQ-NO. <italic>Note:</italic> Each pair of light and dark green dots represents one participant. The figure illustrates improvements in person locations in both subscales 6 months after intervention (reduced person location indicates better functioning/less symptoms) for most participants. The mean person locations improved significantly with intervention</p></caption><graphic xlink:href="41687_2025_896_Fig6_HTML" id="d33e1840"/></fig>
</p></sec></sec><sec id="Sec18"><title>Discussion</title><p id="Par47">The purpose of this study was to translate and adapt KORQ to the Norwegian language, culture, and environment, and to validate KORQ-NO in a Norwegian keratoconus population. The overall results suggest successful translation and cross-cultural adaptation for use in Norway. The content validity of KORQ-NO was confirmed by the satisfaction of participants and experienced optometrists regarding its relevance and comprehensiveness, with few remarks about the content. The Rasch analysis confirmed acceptable psychometric properties of KORQ-NO, resembling the original KORQ [<xref ref-type="bibr" rid="CR15">15</xref>], when assessed without the extra item AL3b <italic>&#x0201c;driving in poor visibility&#x0201d;</italic>.</p><p id="Par48">Reliability and responsiveness are crucial attributes for efficient documentation of improvements, relevant in research, clinical practice, and insurance benefit applications to the Norwegian Labour and Welfare Administration [<xref ref-type="bibr" rid="CR42">42</xref>]. The excellent responsiveness of KORQ-NO confirms the ability to detect change with intervention. To our knowledge, no other validation study has evaluated responsiveness of KORQ, but a clinical study using KORQ before and after corneal collagen crosslinking affirmed this attribute [<xref ref-type="bibr" rid="CR19">19</xref>]. The person separation indexes suggest higher reliability for &#x0201c;Activity limitations&#x0201d; than &#x0201c;Symptoms&#x0201d;, corresponding with results from other studies [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Accordingly, the test-retest reliability of &#x0201c;Activity limitations&#x0201d; was superior of &#x0201c;Symptoms&#x0201d;. Measurement errors, more evident in the &#x0201c;Symptoms&#x0201d; subscale, may be explained by several factors. First, scale recalibration, change in persons&#x02019; understanding of the scale, is a common bias in prospective measurements [<xref ref-type="bibr" rid="CR43">43</xref>]. Second, poor face validity with lack of instructions, leading to participant uncertainty in responding to items, may undermine the test-retest reliability [<xref ref-type="bibr" rid="CR22">22</xref>]. Third, day-to-day fluctuations common in keratoconus potentially add noise and reduce test-retest reliability [<xref ref-type="bibr" rid="CR7">7</xref>]. However, a sample size of seventeen participants is too low to make conclusions. Previously, two validation studies suggested excellent test-retest reliability, as measured by Spearman&#x02019;s correlation coefficients [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], and a third study with larger sample size and less measurement errors confirmed good test-retest reliability for both subscales of KORQ [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par49">Clinical measurements are objective assessments of visual status and response to correction or treatment, whereas PROMs reflect the subjective experience of the visual impairment [<xref ref-type="bibr" rid="CR44">44</xref>]. In the current study, lack of statistically significant correlations between clinical measurements and KORQ-NO might be explained by low sample size, as very few participants presented with impaired corrected visual acuity. Nonetheless, there was a statistically significant difference in person locations on &#x0201c;Activity limitations&#x0201d; among groups with different asymmetry between eyes. The graphical displays indicate tendencies of associations with contrast sensitivity as well. Margolis et al. found weak correlations with visual acuity in most vision-specific PROMs, indicating that subjective measures provide complementary insights [<xref ref-type="bibr" rid="CR44">44</xref>]. These findings are in accordance with studies on keratoconus and associations between VR-QoL and various clinical measurements [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Future investigation with larger sample size is needed for proper assessment of correlations. Other validation studies have shown weak to moderate correlations between clinical measurements and KORQ [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. Nevertheless, the results emphasize the usefulness of KORQ-NO, as it adds important information on how the patient perceive visual function and symptoms [<xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par50">The results suggest superior targeting of KORQ-NO over NEI VFQ-25, affirming higher reliability of KORQ-NO. This supports the use of KORQ-NO in clinical practice and future studies to complement objective measurements of persons with keratoconus, in line with findings that disease-specific PROMs are usually recommended over generic PROMs due to superior sensitivity and validity [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. The psychometric properties of the vision-generic NEI VFQ-25 were questioned by Pesudovs et al. [<xref ref-type="bibr" rid="CR46">46</xref>], congruent with findings in the current study. Regardless, NEI VFQ-25 has been widely used in studies on keratoconus and VR-QoL [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR47">47</xref>], as no keratoconus-specific PROM was available prior to the development of KORQ [<xref ref-type="bibr" rid="CR15">15</xref>]. Consequently, NEI VFQ-25 is the most relevant PROM to use for construct validity, which was confirmed by the strong negative correlations between NEI VFQ-25 and KORQ-NO. Additionally, the results suggest that the conversion spreadsheets provided by Khadka et al. [<xref ref-type="bibr" rid="CR15">15</xref>] may be used in the Norwegian population.</p><p id="Par51">The strengths of the current study include the use of Rasch analysis to evaluate the psychometric properties of KORQ-NO and NEI VFQ-25, and evaluation of test-retest reliability, content and construct validity, and responsiveness. The main limitations are low sample sizes in the retest and clinical groups, as well as the main group for Rasch analysis. Sample size was too low for robust evaluations of DIFs and rating scale [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Additionally, unidimensionality is affected by sample size, and accurate item fit requires a sample size above 200 [<xref ref-type="bibr" rid="CR49">49</xref>]. However, 11 participants are sufficient for ICC indications of good test-retest reliability [<xref ref-type="bibr" rid="CR50">50</xref>], and Rasch analysis with samples 100 may be sufficient when treated with caution and in interaction with qualitative evaluation of the items [<xref ref-type="bibr" rid="CR39">39</xref>]. Data collection through &#x0201c;Nettskjema&#x0201d; was necessary for feasibility of the study but adds limitations. Potential participants inactive on the &#x0201c;Keratoconus Norway&#x0201d; social media platform was excluded, no information regarding the severity of keratoconus was collected, and collecting retest data over the telephone might add uncertainty to the results. Despite this, the results support the use of KORQ-NO. There is a potential for item reduction without compromising content validity, and future work should aim to reduce the number of items and validate the questionnaire with larger sample size, with particular attention to potential DIFs.</p><p id="Par52">The requirements for Rasch analysis and weaknesses of KORQ-NO need to be addressed further, as neither subscale exhibit perfect unidimensionality. However, the results are comparable to findings in other validation studies of KORQ [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. Although the proportion of statistically significant <italic>t-</italic>tests remained higher than ideal in &#x0201c;Activity limitations&#x0201d; after removal of AL3b, the eigenvalue of the first contrast was lower than the original KORQ [<xref ref-type="bibr" rid="CR15">15</xref>] and equal to the Australian validation [<xref ref-type="bibr" rid="CR16">16</xref>]. Deletion of items AL3 <italic>&#x0201c;driving at night&#x0201d;</italic>, AL12 <italic>&#x0201c;doing your hobbies&#x0201d;</italic>, and AL15 <italic>&#x0201c;doing household tasks&#x0201d;</italic> improved dimensionality. DIFs also need to be addressed in the future. With low sample size, DIFs may be results by chance [<xref ref-type="bibr" rid="CR38">38</xref>]. Ideally, validation with higher sample size should be conducted to confirm or disconfirm the present DIFs [<xref ref-type="bibr" rid="CR48">48</xref>]. Finally, the disordered response category thresholds of item AL15 <italic>&#x0201c;doing household tasks&#x0201d;</italic> may also be affected by low sample size [<xref ref-type="bibr" rid="CR38">38</xref>]. However, most participants responded &#x0201c;not at all&#x0201d; to the item, and the retest participants deemed it irrelevant to their condition, justifying the deletion of item AL15 without compromising content validity.</p><p id="Par53">While statistical findings justify removal of AL15, it remains important to consider potential reasons why participants found this item irrelevant beyond sample size limitations. This highlights the broader challenges of cross-cultural adaptation in PROM validation, which involve both methodological and contextual factors. Future research should explore whether discrepancy in item response is due to differences in societal norms, independence in daily living, or varying expectations regarding functional limitations associated with vision impairment. Although there is no global consensus on cross-cultural adaptation of PROMs [<xref ref-type="bibr" rid="CR26">26</xref>], and a multistep methodology described in literature was followed [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>], the process includes strengths and limitations. First, three concurrent, independent translations and the consensus discussion of the translations represents a strength of the translation process. The availability of only one native English-speaking translator within the institution resulted in a single back-translation, which might be perceived as a limitation. However, according to Epstein et al. [<xref ref-type="bibr" rid="CR26">26</xref>], back translation should not be mandatory. Ideally, the cognitive debriefing should have been more comprehensive, with inclusion of more persons representing the target population [<xref ref-type="bibr" rid="CR31">31</xref>]. For practical reasons, only one native Norwegian-speaking lay person assessed the questionnaire, which increases risk of persons misunderstanding of items [<xref ref-type="bibr" rid="CR31">31</xref>]. However, this risk is considered small, as none of the retest participants responding to the questionnaire over the phone expressed uncertainty about the meaning of the items. Further, low numbers of missing data supports low levels of misunderstanding [<xref ref-type="bibr" rid="CR31">31</xref>].</p></sec><sec id="Sec19"><title>Conclusion</title><p id="Par54">Successful translation and adaptation of KORQ to Norwegian language, culture and environment was confirmed by acceptable psychometric properties via Rasch analysis, and evaluations of validity, reliability, and responsiveness. While there is potential for improvements through item reduction of KORQ-NO, the authors support the use of KORQ-NO in research, clinical practice, and as documentation for allowance applications.</p></sec><sec id="Sec20" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41687_2025_896_MOESM1_ESM.pdf"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41687_2025_896_MOESM2_ESM.docx"><caption><p>Supplementary Material 2</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41687_2025_896_MOESM3_ESM.pdf"><caption><p>Supplementary Material 3</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Stuart Gilson, University of South-Eastern Norway, for back-translation from Norwegian to English during the translation process.</p><p>Stuart Gilson, University of South-Eastern Norway, contributed with back-translation from Norwegian to English during the translation process.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>SMR, HKF and VS contributed with translation of KORQ. HKF, VS and EL designed the study protocol. SMR and EL contributed with data collection. Data was analysed by EL and interpreted by VS, HKF, SMR and LL. All authors contributed writing the manuscript, and all authors read and approved the final manuscript.</p><p>Acknowledgements.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by University Of South-Eastern Norway</p><p>The research is conducted by employees at the University of South-Eastern Norway, with no external funding.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The dataset used and analyed during the study are available from the corresponding author on reasonable request. According to the University of South-Eastern Norway Open Access policy, the data will be available in Figshare (<ext-link ext-link-type="uri" xlink:href="https://usn.fishare.com">https://usn.fishare.com</ext-link>) once the article has been published.</p></notes><notes><title>Declarations</title><notes id="FPar3"><title>Ethical approval and consent to participate</title><p id="Par55">Approval was granted by the Norwegian center for research data (SiKT reference number 934897 &#x00026; 953377), and the Regional Committee for Medical Research Ethics (REK 953377). All participants provided written informed consent, either through &#x0201c;Nettskjema&#x0201d; or on paper.</p></notes><notes id="FPar1"><title>Consent for publication</title><p id="Par56">Not applicable.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par57">Not applicable.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>JAP</given-names></name><name><surname>Tan</surname><given-names>D</given-names></name><name><surname>Rapuano</surname><given-names>CJ</given-names></name><name><surname>Belin</surname><given-names>MW</given-names></name><name><surname>Ambr&#x000f3;sio</surname><given-names>RJ</given-names></name><name><surname>Guell</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Global consensus on keratoconus and ectatic diseases</article-title><source>Cornea</source><year>2015</year><volume>34</volume><issue>4</issue><fpage>359</fpage><pub-id pub-id-type="doi">10.1097/ICO.0000000000000408</pub-id><pub-id pub-id-type="pmid">25738235</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Gomes JAP, Tan D, Rapuano CJ, Belin MW, Ambr&#x000f3;sio RJ, Guell JL et al (2015) Global consensus on keratoconus and ectatic diseases. Cornea 34(4):359<pub-id pub-id-type="pmid">25738235</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Ferrer</surname><given-names>FJ</given-names></name><name><surname>Akpek</surname><given-names>EK</given-names></name><name><surname>Amescua</surname><given-names>G</given-names></name><name><surname>Farid</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>A</given-names></name><name><surname>Rhee</surname><given-names>MK</given-names></name><etal/></person-group><source>Corneal Ectasia Preferred Pract Pattern&#x000ae; Ophthalmol</source><year>2019</year><volume>126</volume><issue>1</issue><fpage>P170</fpage><lpage>215</lpage></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Garcia-Ferrer FJ, Akpek EK, Amescua G, Farid M, Lin A, Rhee MK et al (2019) Corneal Ectasia Preferred Pract Pattern<sup>&#x000ae;</sup> Ophthalmol 126(1):P170&#x02013;215</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>G</given-names></name><name><surname>Rama</surname><given-names>P</given-names></name></person-group><article-title>The keratoconus enigma: A review on pathogenesis</article-title><source>Ocul Surf</source><year>2020</year><volume>18</volume><issue>3</issue><fpage>363</fpage><pub-id pub-id-type="doi">10.1016/j.jtos.2020.03.006</pub-id><pub-id pub-id-type="pmid">32234342</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Ferrari G, Rama P (2020) The keratoconus enigma: a review with emphasis on pathogenesis. Ocul Surf 18(3):363. 10.1016/j.jtos.2020.03.006<pub-id pub-id-type="pmid">32234342</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Kristianslund</surname><given-names>O</given-names></name><name><surname>Hagem</surname><given-names>AM</given-names></name><name><surname>Thorsrud</surname><given-names>A</given-names></name><name><surname>Drolsum</surname><given-names>L</given-names></name></person-group><article-title>Prevalence and incidence of keratoconus in Norway: a nationwide register study</article-title><source>Acta Ophthalmol (Copenh)</source><year>2021</year><volume>99</volume><issue>5</issue><fpage>e694</fpage><lpage>e699</lpage><pub-id pub-id-type="doi">10.1111/aos.14668</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Kristianslund O, Hagem AM, Thorsrud A, Drolsum L (2021) Prevalence and incidence of keratoconus in Norway: a nationwide register study. Acta Ophthalmol (Copenh) 99(5):e694&#x02013;e699</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Gothwal</surname><given-names>VK</given-names></name><name><surname>Reddy</surname><given-names>SP</given-names></name><name><surname>Fathima</surname><given-names>A</given-names></name><name><surname>Bharani</surname><given-names>S</given-names></name><name><surname>Sumalini</surname><given-names>R</given-names></name><name><surname>Bagga</surname><given-names>DK</given-names></name><etal/></person-group><article-title>Assessment of the impact of keratoconus on Vision-Related quality of life</article-title><source>Invest Ophthalmol Vis Sci</source><year>2013</year><volume>54</volume><issue>4</issue><fpage>2902</fpage><lpage>2910</lpage><pub-id pub-id-type="doi">10.1167/iovs.12-10783</pub-id><pub-id pub-id-type="pmid">23518765</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Gothwal VK, Reddy SP, Fathima A, Bharani S, Sumalini R, Bagga DK et al (2013) Assessment of the impact of keratoconus on Vision-Related quality of life. Invest Ophthalmol Vis Sci 54(4):2902&#x02013;2910<pub-id pub-id-type="pmid">23518765</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Kymes</surname><given-names>SM</given-names></name><name><surname>Walline</surname><given-names>JJ</given-names></name><name><surname>Zadnik</surname><given-names>K</given-names></name><name><surname>Gordon</surname><given-names>MO</given-names></name></person-group><article-title>Collaborative longitudinal evaluation of keratoconus study group. Quality of life in keratoconus</article-title><source>Am J Ophthalmol</source><year>2004</year><volume>138</volume><issue>4</issue><fpage>527</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2004.04.031</pub-id><pub-id pub-id-type="pmid">15488776</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Kymes SM, Walline JJ, Zadnik K, Gordon MO (2004) Collaborative longitudinal evaluation of keratoconus study group. Quality of life in keratoconus. Am J Ophthalmol 138(4):527&#x02013;535<pub-id pub-id-type="pmid">15488776</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Santodomingo-Rubido</surname><given-names>J</given-names></name><name><surname>Carracedo</surname><given-names>G</given-names></name><name><surname>Suzaki</surname><given-names>A</given-names></name><name><surname>Villa-Collar</surname><given-names>C</given-names></name><name><surname>Vincent</surname><given-names>SJ</given-names></name><name><surname>Wolffsohn</surname><given-names>JS</given-names></name></person-group><article-title>Keratoconus: an updated review</article-title><source>Contact Lens Anterior Eye</source><year>2022</year><volume>45</volume><issue>3</issue><fpage>101559</fpage><pub-id pub-id-type="doi">10.1016/j.clae.2021.101559</pub-id><pub-id pub-id-type="pmid">34991971</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Santodomingo-Rubido J, Carracedo G, Suzaki A, Villa-Collar C, Vincent SJ, Wolffsohn JS (2022) Keratoconus: an updated review. Contact Lens Anterior Eye 45(3):101559<pub-id pub-id-type="pmid">34991971</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Braithwaite</surname><given-names>T</given-names></name><name><surname>Calvert</surname><given-names>M</given-names></name><name><surname>Gray</surname><given-names>A</given-names></name><name><surname>Pesudovs</surname><given-names>K</given-names></name><name><surname>Denniston</surname><given-names>AK</given-names></name></person-group><article-title>The use of patient-reported outcome research in modern ophthalmology: impact on clinical trials and routine clinical practice</article-title><source>Patient Relat Outcome Meas</source><year>2019</year><volume>10</volume><fpage>9</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.2147/PROM.S162802</pub-id><pub-id pub-id-type="pmid">30774489</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Braithwaite T, Calvert M, Gray A, Pesudovs K, Denniston AK (2019) The use of patient-reported outcome research in modern ophthalmology: impact on clinical trials and routine clinical practice. Patient Relat Outcome Meas 10:9&#x02013;24<pub-id pub-id-type="pmid">30774489</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Mangione</surname><given-names>CM</given-names></name><name><surname>Lee</surname><given-names>PP</given-names></name><name><surname>Gutierrez</surname><given-names>PR</given-names></name><name><surname>Spritzer</surname><given-names>K</given-names></name><name><surname>Berry</surname><given-names>S</given-names></name><name><surname>Hays</surname><given-names>RD</given-names></name></person-group><article-title>Development of the 25-list-item National eye Institute visual function questionnaire</article-title><source>JAMA Ophthalmol</source><year>2001</year><volume>119</volume><issue>7</issue><fpage>1050</fpage><lpage>1058</lpage></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD (2001) Development of the 25-list-item National eye Institute visual function questionnaire. JAMA Ophthalmol 119(7):1050&#x02013;1058</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Kymes</surname><given-names>SM</given-names></name><name><surname>Walline</surname><given-names>JJ</given-names></name><name><surname>Zadnik</surname><given-names>K</given-names></name><name><surname>Sterling</surname><given-names>J</given-names></name><name><surname>Gordon</surname><given-names>MO</given-names></name></person-group><article-title>Changes in the Quality-of-Life of people with keratoconus</article-title><source>Am J Ophthalmol</source><year>2008</year><volume>145</volume><issue>4</issue><fpage>611</fpage><lpage>617e1</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2007.11.017</pub-id><pub-id pub-id-type="pmid">18226798</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Kymes SM, Walline JJ, Zadnik K, Sterling J, Gordon MO (2008) Changes in the Quality-of-Life of people with keratoconus. Am J Ophthalmol 145(4):611&#x02013;617e1<pub-id pub-id-type="pmid">18226798</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Jones-Jordan</surname><given-names>LA</given-names></name><name><surname>Walline</surname><given-names>JJ</given-names></name><name><surname>Sinnott</surname><given-names>LT</given-names></name><name><surname>Kymes</surname><given-names>SM</given-names></name><name><surname>Zadnik</surname><given-names>K</given-names></name></person-group><article-title>Asymmetry in keratoconus and Vision-Related quality of life</article-title><source>Cornea</source><year>2013</year><volume>32</volume><issue>3</issue><fpage>267</fpage><pub-id pub-id-type="doi">10.1097/ICO.0b013e31825697c4</pub-id><pub-id pub-id-type="pmid">22825402</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Jones-Jordan LA, Walline JJ, Sinnott LT, Kymes SM, Zadnik K (2013) Asymmetry in keratoconus and Vision-Related quality of life. Cornea 32(3):267<pub-id pub-id-type="pmid">22825402</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000fc;mmer</surname><given-names>L</given-names></name><name><surname>Kreps</surname><given-names>EO</given-names></name><name><surname>Pesudovs</surname><given-names>K</given-names></name><name><surname>Berwouts</surname><given-names>J</given-names></name><name><surname>Estramil</surname><given-names>N</given-names></name><name><surname>Mathysen</surname><given-names>DGP</given-names></name><etal/></person-group><article-title>Investigating the link between visual quality and Vision-Related quality of life in patients with keratoconus</article-title><source>Cornea</source><year>2023</year><volume>42</volume><issue>10</issue><fpage>1280</fpage><lpage>1285</lpage><pub-id pub-id-type="doi">10.1097/ICO.0000000000003200</pub-id><pub-id pub-id-type="pmid">36729659</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Sch&#x000fc;mmer L, Kreps EO, Pesudovs K, Berwouts J, Estramil N, Mathysen DGP et al (2023) Investigating the link between visual quality and Vision-Related quality of life in patients with keratoconus. Cornea 42(10):1280&#x02013;1285<pub-id pub-id-type="pmid">36729659</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Ortiz-Toquero</surname><given-names>S</given-names></name><name><surname>Perez</surname><given-names>S</given-names></name><name><surname>Rodriguez</surname><given-names>G</given-names></name><name><surname>de Juan</surname><given-names>V</given-names></name><name><surname>Mayo-Iscar</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>R</given-names></name></person-group><article-title>The influence of the refractive correction on the vision-related quality of life in keratoconus patients</article-title><source>Qual Life Res Int J Qual Life Asp Treat Care Rehabil</source><year>2016</year><volume>25</volume><issue>4</issue><fpage>1043</fpage><lpage>1051</lpage></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Ortiz-Toquero S, Perez S, Rodriguez G, de Juan V, Mayo-Iscar A, Martin R (2016) The influence of the refractive correction on the vision-related quality of life in keratoconus patients. Qual Life Res Int J Qual Life Asp Treat Care Rehabil 25(4):1043&#x02013;1051</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Churruca</surname><given-names>K</given-names></name><name><surname>Pomare</surname><given-names>C</given-names></name><name><surname>Ellis</surname><given-names>LA</given-names></name><name><surname>Long</surname><given-names>JC</given-names></name><name><surname>Henderson</surname><given-names>SB</given-names></name><name><surname>Murphy</surname><given-names>LED</given-names></name><etal/></person-group><article-title>Patient-reported outcome measures (PROMs): A review of generic and condition-specific measures and a discussion of trends and issues</article-title><source>Health Expect</source><year>2021</year><volume>24</volume><issue>4</issue><fpage>1015</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1111/hex.13254</pub-id><pub-id pub-id-type="pmid">33949755</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Churruca K, Pomare C, Ellis LA, Long JC, Henderson SB, Murphy LED et al (2021) Patient-reported outcome measures (PROMs): A review of generic and condition-specific measures and a discussion of trends and issues. Health Expect 24(4):1015&#x02013;1024<pub-id pub-id-type="pmid">33949755</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Khadka</surname><given-names>J</given-names></name><name><surname>Schoneveld</surname><given-names>PG</given-names></name><name><surname>Pesudovs</surname><given-names>K</given-names></name></person-group><article-title>Development of a Keratoconus-Specific questionnaire using Rasch analysis</article-title><source>Optom Vis Sci</source><year>2017</year><volume>94</volume><issue>3</issue><fpage>395</fpage><pub-id pub-id-type="doi">10.1097/OPX.0000000000001035</pub-id><pub-id pub-id-type="pmid">28027275</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Khadka J, Schoneveld PG, Pesudovs K (2017) Development of a Keratoconus-Specific questionnaire using Rasch analysis. Optom Vis Sci 94(3):395<pub-id pub-id-type="pmid">28027275</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Kandel</surname><given-names>H</given-names></name><name><surname>Pesudovs</surname><given-names>K</given-names></name><name><surname>Ferdi</surname><given-names>A</given-names></name><name><surname>Mills</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>JY</given-names></name><name><surname>Watson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Psychometric properties of the keratoconus outcomes research questionnaire: A save sight keratoconus registry study</article-title><source>Cornea</source><year>2020</year><volume>39</volume><issue>3</issue><fpage>303</fpage><pub-id pub-id-type="doi">10.1097/ICO.0000000000002169</pub-id><pub-id pub-id-type="pmid">31634230</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Kandel H, Pesudovs K, Ferdi A, Mills R, Chen JY, Watson A et al (2020) Psychometric properties of the keratoconus outcomes research questionnaire: A save sight keratoconus registry study. Cornea 39(3):303<pub-id pub-id-type="pmid">31634230</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Gothwal</surname><given-names>VK</given-names></name><name><surname>Gujar</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Begum</surname><given-names>N</given-names></name><name><surname>Pesudovs</surname><given-names>K</given-names></name></person-group><article-title>Factors affecting quality of life in keratoconus</article-title><source>Ophthalmic Physiol Opt</source><year>2022</year><volume>42</volume><issue>5</issue><fpage>986</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1111/opo.13010</pub-id><pub-id pub-id-type="pmid">35638140</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Gothwal VK, Gujar R, Sharma S, Begum N, Pesudovs K (2022) Factors affecting quality of life in keratoconus. Ophthalmic Physiol Opt 42(5):986&#x02013;997<pub-id pub-id-type="pmid">35638140</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Bak-Nielsen</surname><given-names>S</given-names></name><name><surname>Groenborg</surname><given-names>TK</given-names></name><name><surname>Ivarsen</surname><given-names>A</given-names></name><name><surname>Hjortdal</surname><given-names>J</given-names></name></person-group><article-title>The keratoconus outcome research questionnaire: A Cross-Cultural validation study of the Danish version</article-title><source>Cornea</source><year>2020</year><volume>39</volume><issue>8</issue><fpage>998</fpage><pub-id pub-id-type="doi">10.1097/ICO.0000000000002354</pub-id><pub-id pub-id-type="pmid">32452989</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Bak-Nielsen S, Groenborg TK, Ivarsen A, Hjortdal J (2020) The keratoconus outcome research questionnaire: A Cross-Cultural validation study of the Danish version. Cornea 39(8):998<pub-id pub-id-type="pmid">32452989</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Ferrini E, Aleo D, Posarelli C, Albert T, Miccoli M, Orr&#x000f9; G et al (2021) The Italian version of the keratoconus outcomes research questionnaire (KORQ): translation and validation of psychometric properties. Eur J Ophthalmol 31(6):3511&#x02013;3517</mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>RDP</given-names></name><name><surname>Abe</surname><given-names>RY</given-names></name><name><surname>Gomes</surname><given-names>FC</given-names></name><name><surname>Barbisan</surname><given-names>PRT</given-names></name><name><surname>Martini</surname><given-names>AF</given-names></name><name><surname>de Almeida Borges</surname><given-names>D</given-names></name><etal/></person-group><article-title>Quality of life in keratoconus: evaluation with keratoconus outcomes research questionnaire (KORQ)</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><issue>1</issue><fpage>12970</fpage><lpage>12970</lpage><pub-id pub-id-type="doi">10.1038/s41598-021-92346-1</pub-id><pub-id pub-id-type="pmid">34155238</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Pinto RDP, Abe RY, Gomes FC, Barbisan PRT, Martini AF, de Almeida Borges D et al (2021) Quality of life in keratoconus: evaluation with keratoconus outcomes research questionnaire (KORQ). Sci Rep 11(1):12970&#x02013;12970<pub-id pub-id-type="pmid">34155238</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Balparda</surname><given-names>K</given-names></name><name><surname>Galarreta-Mira</surname><given-names>D</given-names></name><name><surname>Vanegas-Ram&#x000ed;rez</surname><given-names>CM</given-names></name></person-group><article-title>Translation and validation of the questionnaire for research on keratoconus results (KORQ) in the Colombian population</article-title><source>Arch Soc Esp Oftalmol Engl Ed</source><year>2020</year><volume>95</volume><issue>12</issue><fpage>579</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1016/j.oftal.2020.05.037</pub-id><pub-id pub-id-type="pmid">32788064</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Balparda K, Galarreta-Mira D, Vanegas-Ram&#x000ed;rez CM (2020) Translation and validation of the questionnaire for research on keratoconus results (KORQ) in the Colombian population. Arch Soc Esp Oftalmol Engl Ed 95(12):579&#x02013;585<pub-id pub-id-type="pmid">32788064</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Pomberger L, Tasch L, Lundstr&#x000f6;m M, Waser K, Khalil H, Kronschl&#x000e4;ger M et al (2024) Evaluation of the German Version of the Keratoconus Outcomes Research Questionnaire. Cornea</mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">The Norwegian Insurance Act Lov om folketrygd (folketrygdloven) - Kapittel 10. St&#x000f8;nad for &#x000e5; kompensere for utgifter til bedring av arbeidsevnen og funksjonsevnen i&#x02026; Lovdata [Internet]. 2008 [cited 2024 Aug 7]. Available from: <ext-link ext-link-type="uri" xlink:href="https://lovdata.no/dokument/NL/lov/1997-02-28-19/KAPITTEL_5-6#KAPITTEL_5-6">https://lovdata.no/dokument/NL/lov/1997-02-28-19/KAPITTEL_5-6#KAPITTEL_5-6</ext-link></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">The Norwegian Labour and Welfare Administration Vedlegg 7 til ftrl &#x000a7; 10&#x02013;&#x02009;7 a, c, d samt annet og tredje ledd&#x02013; Regler for s&#x000e6;rskilte hjelpemiddelgrupper - Lovdata [Internet]. 2024 [cited 2024 Aug 7]. Available from: <ext-link ext-link-type="uri" xlink:href="https://lovdata.no/nav/rundskriv/v7-10-07acd?q=keratokonus#KAPITTEL_4-12">https://lovdata.no/nav/rundskriv/v7-10-07acd?q=keratokonus#KAPITTEL_4-12</ext-link></mixed-citation></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Acquadro</surname><given-names>C</given-names></name><name><surname>Conway</surname><given-names>K</given-names></name><name><surname>Hareendran</surname><given-names>A</given-names></name><name><surname>Aaronson</surname><given-names>N</given-names></name></person-group><article-title>Literature review of methods to translate Health-Related quality of life questionnaires for use in multinational clinical trials</article-title><source>Value Health</source><year>2008</year><volume>11</volume><issue>3</issue><fpage>509</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1111/j.1524-4733.2007.00292.x</pub-id><pub-id pub-id-type="pmid">18179659</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Acquadro C, Conway K, Hareendran A, Aaronson N (2008) Literature review of methods to translate Health-Related quality of life questionnaires for use in multinational clinical trials. Value Health 11(3):509&#x02013;521<pub-id pub-id-type="pmid">18179659</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>J</given-names></name><name><surname>Santo</surname><given-names>RM</given-names></name><name><surname>Guillemin</surname><given-names>F</given-names></name></person-group><article-title>A review of guidelines for cross-cultural adaptation of questionnaires could not bring out a consensus</article-title><source>J Clin Epidemiol</source><year>2015</year><volume>68</volume><issue>4</issue><fpage>435</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2014.11.021</pub-id><pub-id pub-id-type="pmid">25698408</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Epstein J, Santo RM, Guillemin F (2015) A review of guidelines for cross-cultural adaptation of questionnaires could not bring out a consensus. J Clin Epidemiol 68(4):435&#x02013;441<pub-id pub-id-type="pmid">25698408</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Mokkink</surname><given-names>LB</given-names></name><name><surname>Terwee</surname><given-names>CB</given-names></name><name><surname>Patrick</surname><given-names>DL</given-names></name><name><surname>Alonso</surname><given-names>J</given-names></name><name><surname>Stratford</surname><given-names>PW</given-names></name><name><surname>Knol</surname><given-names>DL</given-names></name><etal/></person-group><article-title>The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study</article-title><source>Qual Life Res</source><year>2010</year><volume>19</volume><issue>4</issue><fpage>539</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1007/s11136-010-9606-8</pub-id><pub-id pub-id-type="pmid">20169472</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL et al (2010) The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res 19(4):539&#x02013;549<pub-id pub-id-type="pmid">20169472</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Mokkink LB, Prinsen CA, Patrick DL, Alonso J, Bouter LM, de Vet HC et al (2019) COSMIN Study Design checklist for Patient-reported outcome measurement instruments. COSMIN [Internet] Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cosmin.nl/wp-content/uploads/COSMIN-study-designing-checklist_final.pdf">https://www.cosmin.nl/wp-content/uploads/COSMIN-study-designing-checklist_final.pdf</ext-link></mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Mokkink</surname><given-names>LB</given-names></name><name><surname>Terwee</surname><given-names>CB</given-names></name><name><surname>Knol</surname><given-names>DL</given-names></name><name><surname>Stratford</surname><given-names>PW</given-names></name><name><surname>Alonso</surname><given-names>J</given-names></name><name><surname>Patrick</surname><given-names>DL</given-names></name><etal/></person-group><article-title>The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: A clarification of its content</article-title><source>BMC Med Res Methodol</source><year>2010</year><volume>10</volume><issue>1</issue><fpage>22</fpage><pub-id pub-id-type="doi">10.1186/1471-2288-10-22</pub-id><pub-id pub-id-type="pmid">20298572</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Mokkink LB, Terwee CB, Knol DL, Stratford PW, Alonso J, Patrick DL et al (2010) The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: A clarification of its content. BMC Med Res Methodol 10(1):22<pub-id pub-id-type="pmid">20298572</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Santo</surname><given-names>RM</given-names></name><name><surname>Ribeiro-Ferreira</surname><given-names>F</given-names></name><name><surname>Alves</surname><given-names>MR</given-names></name><name><surname>Epstein</surname><given-names>J</given-names></name><name><surname>Novaes</surname><given-names>P</given-names></name></person-group><article-title>Enhancing the cross-cultural adaptation and validation process: linguistic and psychometric testing of the Brazilian&#x02013;Portuguese version of a self-report measure for dry eye</article-title><source>J Clin Epidemiol</source><year>2015</year><volume>68</volume><issue>4</issue><fpage>370</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2014.07.009</pub-id><pub-id pub-id-type="pmid">25619561</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Santo RM, Ribeiro-Ferreira F, Alves MR, Epstein J, Novaes P (2015) Enhancing the cross-cultural adaptation and validation process: linguistic and psychometric testing of the Brazilian&#x02013;Portuguese version of a self-report measure for dry eye. J Clin Epidemiol 68(4):370&#x02013;378<pub-id pub-id-type="pmid">25619561</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Wild</surname><given-names>D</given-names></name><name><surname>Grove</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Eremenco</surname><given-names>S</given-names></name><name><surname>McElroy</surname><given-names>S</given-names></name><name><surname>Verjee-Lorenz</surname><given-names>A</given-names></name><etal/></person-group><article-title>Principles of good practice for the translation and cultural adaptation process for Patient-Reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation</article-title><source>Value Health</source><year>2005</year><volume>8</volume><issue>2</issue><fpage>94</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1111/j.1524-4733.2005.04054.x</pub-id><pub-id pub-id-type="pmid">15804318</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A et al (2005) Principles of good practice for the translation and cultural adaptation process for Patient-Reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health 8(2):94&#x02013;104<pub-id pub-id-type="pmid">15804318</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Jelin</surname><given-names>E</given-names></name><name><surname>Wisl&#x000f8;ff</surname><given-names>T</given-names></name><name><surname>Moe</surname><given-names>MC</given-names></name><name><surname>Heiberg</surname><given-names>T</given-names></name></person-group><article-title>Psychometric properties of the National eye Institute visual function questionnaire (NEI-VFQ 25) in a Norwegian population of patients with neovascular age-related macular degeneration compared to a control population</article-title><source>Health Qual Life Outcomes</source><year>2019</year><volume>17</volume><issue>1</issue><fpage>140</fpage><pub-id pub-id-type="doi">10.1186/s12955-019-1203-0</pub-id><pub-id pub-id-type="pmid">31412873</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Jelin E, Wisl&#x000f8;ff T, Moe MC, Heiberg T (2019) Psychometric properties of the National eye Institute visual function questionnaire (NEI-VFQ 25) in a Norwegian population of patients with neovascular age-related macular degeneration compared to a control population. Health Qual Life Outcomes 17(1):140<pub-id pub-id-type="pmid">31412873</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">World Medical Association WMA Declaration of Helsinki&#x02013; Ethical Principles for Medical Research Involving Human Participants [Internet]. 2024 [cited 2025 Mar 10]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.wma.net/policies-post/wma-declaration-of-helsinki/">https://www.wma.net/policies-post/wma-declaration-of-helsinki/</ext-link></mixed-citation></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Tennant</surname><given-names>A</given-names></name><name><surname>Conaghan</surname><given-names>PG</given-names></name></person-group><article-title>The Rasch measurement model in rheumatology: what is it and why use it? When should it be applied, and what should one look for in a Rasch paper?</article-title><source>Arthritis Care Res</source><year>2007</year><volume>57</volume><issue>8</issue><fpage>1358</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1002/art.23108</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Tennant A, Conaghan PG (2007) The Rasch measurement model in rheumatology: what is it and why use it? When should it be applied, and what should one look for in a Rasch paper? Arthritis Care Res 57(8):1358&#x02013;1362</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>de Winckel</surname><given-names>AV</given-names></name><name><surname>Kozlowski</surname><given-names>AJ</given-names></name><name><surname>Johnston</surname><given-names>MV</given-names></name><name><surname>Weaver</surname><given-names>J</given-names></name><name><surname>Grampurohit</surname><given-names>N</given-names></name><name><surname>Terhorst</surname><given-names>L</given-names></name><etal/></person-group><article-title>Reporting guideline for RULER: Rasch reporting guideline for rehabilitation research: explanation and elaboration</article-title><source>Arch Phys Med Rehabil</source><year>2022</year><volume>103</volume><issue>7</issue><fpage>1487</fpage><lpage>1498</lpage><pub-id pub-id-type="doi">10.1016/j.apmr.2022.03.019</pub-id><pub-id pub-id-type="pmid">35436496</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">de Winckel AV, Kozlowski AJ, Johnston MV, Weaver J, Grampurohit N, Terhorst L et al (2022) Reporting guideline for RULER: Rasch reporting guideline for rehabilitation research: explanation and elaboration. Arch Phys Med Rehabil 103(7):1487&#x02013;1498<pub-id pub-id-type="pmid">35436496</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Hagquist</surname><given-names>C</given-names></name><name><surname>Bruce</surname><given-names>M</given-names></name><name><surname>Gustavsson</surname><given-names>JP</given-names></name></person-group><article-title>Using the Rasch model in nursing research: an introduction and illustrative example</article-title><source>Int J Nurs Stud</source><year>2009</year><volume>46</volume><issue>3</issue><fpage>380</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1016/j.ijnurstu.2008.10.007</pub-id><pub-id pub-id-type="pmid">19059593</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Hagquist C, Bruce M, Gustavsson JP (2009) Using the Rasch model in nursing research: an introduction and illustrative example. Int J Nurs Stud 46(3):380&#x02013;393<pub-id pub-id-type="pmid">19059593</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Andrich D, Sheridan B Rumm 2030&#x02009;+&#x02009;Version 5.8.1 for Windows [Internet]. 2024 [cited 2024 Jun 27]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.rummlab.com.au/">https://www.rummlab.com.au/</ext-link></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Andrich D, Marais I (2019) A Course in Rasch Measurement Theory: Measuring in the Educational, Social and Health Sciences [Internet]. Singapore: Springer Nature Singapore; [cited 2024 Jan 30]. (Springer Texts in Education). Available from: <ext-link ext-link-type="uri" xlink:href="https://link.springer.com/">https://link.springer.com/</ext-link>10.1007/978-981-13-7496-8</mixed-citation></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WH</given-names></name><name><surname>Lenderking</surname><given-names>W</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Wyrwich</surname><given-names>KW</given-names></name><name><surname>Gelhorn</surname><given-names>H</given-names></name><name><surname>Revicki</surname><given-names>DA</given-names></name></person-group><article-title>Is Rasch model analysis applicable in small sample size pilot studies for assessing item characteristics? An example using PROMIS pain behavior item bank data</article-title><source>Qual Life Res</source><year>2014</year><volume>23</volume><issue>2</issue><fpage>485</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1007/s11136-013-0487-5</pub-id><pub-id pub-id-type="pmid">23912855</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Chen WH, Lenderking W, Jin Y, Wyrwich KW, Gelhorn H, Revicki DA (2014) Is Rasch model analysis applicable in small sample size pilot studies for assessing item characteristics? An example using PROMIS pain behavior item bank data. Qual Life Res 23(2):485&#x02013;493<pub-id pub-id-type="pmid">23912855</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Tennant A, K&#x000fc;&#x000e7;&#x000fc;kdeveci AA Application of the Rasch measurement model in rehabilitation research and practice: early developments, current practice, and future challenges. Front Rehabil Sci [Internet]. 2023 [cited 2024 Mar 1];4. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/">https://www.frontiersin.org/articles/</ext-link>10.3389/fresc.2023.1208670</mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">IBM C. IBM SPSS Statistics for Windows (Version 29.0) [Internet] (2024) Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ibm.com/products/spss-statistics">https://www.ibm.com/products/spss-statistics</ext-link></mixed-citation></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Pesudovs</surname><given-names>K</given-names></name><name><surname>Burr</surname><given-names>JM</given-names></name><name><surname>Harley</surname><given-names>C</given-names></name><name><surname>Elliott</surname><given-names>DB</given-names></name></person-group><article-title>The development, assessment, and selection of questionnaires</article-title><source>Optom Vis Sci</source><year>2007</year><volume>84</volume><issue>8</issue><fpage>663</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1097/OPX.0b013e318141fe75</pub-id><pub-id pub-id-type="pmid">17700331</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Pesudovs K, Burr JM, Harley C, Elliott DB (2007) The development, assessment, and selection of questionnaires. Optom Vis Sci 84(8):663&#x02013;674<pub-id pub-id-type="pmid">17700331</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Blome</surname><given-names>C</given-names></name><name><surname>Augustin</surname><given-names>M</given-names></name></person-group><article-title>Measuring change in quality of life: Bias in prospective and retrospective evaluation</article-title><source>Value Health</source><year>2015</year><volume>18</volume><issue>1</issue><fpage>110</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.jval.2014.10.007</pub-id><pub-id pub-id-type="pmid">25595241</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Blome C, Augustin M (2015) Measuring change in quality of life: Bias in prospective and retrospective evaluation. Value Health 18(1):110&#x02013;115<pub-id pub-id-type="pmid">25595241</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Margolis</surname><given-names>MK</given-names></name><name><surname>Coyne</surname><given-names>K</given-names></name><name><surname>Kennedy-Martin</surname><given-names>T</given-names></name><name><surname>Baker</surname><given-names>T</given-names></name><name><surname>Schein</surname><given-names>O</given-names></name><name><surname>Revicki</surname><given-names>DA</given-names></name></person-group><article-title>Vision-Specific instruments for the assessment of Health-Related quality of life and visual functioning</article-title><source>PharmacoEconomics</source><year>2002</year><volume>20</volume><issue>12</issue><fpage>791</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.2165/00019053-200220120-00001</pub-id><pub-id pub-id-type="pmid">12236802</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Margolis MK, Coyne K, Kennedy-Martin T, Baker T, Schein O, Revicki DA (2002) Vision-Specific instruments for the assessment of Health-Related quality of life and visual functioning. PharmacoEconomics 20(12):791&#x02013;812<pub-id pub-id-type="pmid">12236802</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>JCK</given-names></name><name><surname>Nguyen</surname><given-names>V</given-names></name><name><surname>Fenwick</surname><given-names>E</given-names></name><name><surname>Ferdi</surname><given-names>A</given-names></name><name><surname>Dinh</surname><given-names>A</given-names></name><name><surname>Watson</surname><given-names>SL</given-names></name></person-group><article-title>Vision-Related quality of life in keratoconus: A save sight keratoconus registry study</article-title><source>Cornea</source><year>2019</year><volume>38</volume><issue>5</issue><fpage>600</fpage><pub-id pub-id-type="doi">10.1097/ICO.0000000000001899</pub-id><pub-id pub-id-type="pmid">30730335</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Tan JCK, Nguyen V, Fenwick E, Ferdi A, Dinh A, Watson SL (2019) Vision-Related quality of life in keratoconus: A save sight keratoconus registry study. Cornea 38(5):600<pub-id pub-id-type="pmid">30730335</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Pesudovs</surname><given-names>K</given-names></name><name><surname>Gothwal</surname><given-names>VK</given-names></name><name><surname>Wright</surname><given-names>T</given-names></name><name><surname>Lamoureux</surname><given-names>EL</given-names></name></person-group><article-title>Remediating serious flaws in the National eye Institute visual function questionnaire</article-title><source>J Cataract Refract Surg</source><year>2010</year><volume>36</volume><issue>5</issue><fpage>718</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1016/j.jcrs.2009.11.019</pub-id><pub-id pub-id-type="pmid">20457362</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Pesudovs K, Gothwal VK, Wright T, Lamoureux EL (2010) Remediating serious flaws in the National eye Institute visual function questionnaire. J Cataract Refract Surg 36(5):718&#x02013;732<pub-id pub-id-type="pmid">20457362</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Ortiz-Toquero</surname><given-names>S</given-names></name><name><surname>Perez</surname><given-names>S</given-names></name><name><surname>Rodriguez</surname><given-names>G</given-names></name><name><surname>de Juan</surname><given-names>V</given-names></name><name><surname>Mayo-Iscar</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>R</given-names></name></person-group><article-title>The influence of the refractive correction on the vision-related quality of life in keratoconus patients</article-title><source>Qual Life Res</source><year>2016</year><volume>25</volume><issue>4</issue><fpage>1043</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1007/s11136-015-1117-1</pub-id><pub-id pub-id-type="pmid">26334843</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Ortiz-Toquero S, Perez S, Rodriguez G, de Juan V, Mayo-Iscar A, Martin R (2016) The influence of the refractive correction on the vision-related quality of life in keratoconus patients. Qual Life Res 25(4):1043&#x02013;1051<pub-id pub-id-type="pmid">26334843</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">Myers ND, Wolfe EW, Feltz DL, Penfield RD Identifying Differential Item Functioning of Rating Scale Items With the Rasch Model: An Introduction and an Application [Internet]. 2006 [cited 2024 Jul 1]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.tandfonline.com/doi/epdf/10.1207/s15327841mpee1004_1?needAccess=true">https://www.tandfonline.com/doi/epdf/10.1207/s15327841mpee1004_1?needAccess=true</ext-link></mixed-citation></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Hagell</surname><given-names>P</given-names></name></person-group><article-title>Testing rating scale unidimensionality using the principal component analysis (PCA)/t-Test protocol with the Rasch model: the primacy of theory over statistics</article-title><source>Open J Stat</source><year>2014</year><volume>4</volume><issue>6</issue><fpage>456</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.4236/ojs.2014.46044</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Hagell P (2014) Testing rating scale unidimensionality using the principal component analysis (PCA)/t-Test protocol with the Rasch model: the primacy of theory over statistics. Open J Stat 4(6):456&#x02013;465</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="book"><person-group person-group-type="author"><name><surname>Fayers</surname><given-names>PM</given-names></name></person-group><source>The quality of life: the assessment, analysis and reporting of patient-reported outcomes</source><year>2016</year><edition>3</edition><publisher-loc>Chichester, England</publisher-loc><publisher-name>Wiley Blackwell</publisher-name><fpage>651</fpage></element-citation><mixed-citation id="mc-CR50" publication-type="book">Fayers PM (2016) The quality of life: the assessment, analysis and reporting of patient-reported outcomes, 3rd edn. Wiley Blackwell, Chichester, England, p 651. (THEi Wiley ebooks)</mixed-citation></citation-alternatives></ref></ref-list></back></article>